Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recaticimab Phase 1b/2 in Hyperlipidemia
NCT03944109Phase 2Completed
- Sponsor
- Hengrui
- Start
- Jun 2019
- Primary completion
- Dec 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of recaticimab in hyperlipidemia and hypercholesterolemia (7 arms), sponsored by Hengrui. Primary endpoints: Percent change from baseline to end of the dosing interval in Low-Density Lipoprotein Cholesterol at Day 169 and Number of subjects with adverse events at Day 169. Started Jun 2019; status: completed.
02
Drugs
recaticimab
03
Conditions
hyperlipidemiahypercholesterolemia
Beyond the preview
Go deeper on NCT03944109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03944109.